Should I Join a Clinical Trial?

Every treatment that exists for Alzheimer's today was tested on people who said yes. Saying yes means screening, regular visits and the right to leave at any time.

Why would someone with dementia join a clinical trial?

For some people it is a chance at a treatment early. For many it is something else: a way to make the diagnosis count for something.

People give a mix of reasons. Some want access to a drug that is not available yet. Some value the close monitoring, the scans, the regular visits with a team that specializes in memory. And many say plainly that they want what happened to them to help someone else.

That last reason has a track record. Lecanemab (Leqembi), one of the first drugs shown to slow Alzheimer's, was approved after the Clarity AD trial, published in the New England Journal of Medicine in 2023. It enrolled 1,795 people with early Alzheimer's disease. Over 18 months, lecanemab slowed decline on the main measure by about 27% compared with placebo. It also showed the risks: about 13% of people on the drug had brain swelling on their scans, called ARIA-E, compared with about 2% on placebo. Every one of those numbers came from people who agreed to find out.

You do not owe research anything. But if you are drawn to it, the early stage is when you have the most choice about which study and how.

What does being in a trial actually involve?

Screening first, then regular visits for months or years. Some visits are short, some involve scans, blood draws or a spinal tap. It depends heavily on the study.

• Screening. Before you are enrolled, the team checks whether you meet the study's requirements: memory test scores, scan or blood results, other health conditions and medications. Many people are screened and not enrolled, which says nothing about you. It means that study is looking for something specific.
• A study partner. Most dementia drug trials ask you to name someone who sees you often and can come to some visits and answer questions about how you are doing day to day.
• Visits. Infusion trials can mean a visit every two or four weeks. Observational studies, which follow people without giving a drug, may mean one visit a year.
• Tests. Memory and thinking tests, blood draws, MRI scans for safety, sometimes PET scans or a lumbar puncture.
• Not every study tests a drug. Many look at exercise, diet, sleep, hearing, devices, or simply follow people over time. Those usually ask less of you and carry fewer risks.

Will I get a placebo?

In many drug trials, some people do, and you may not be told which group you were in until the study ends. You will always be told beforehand that a placebo is possible.

In a randomized trial, people are assigned by chance to the experimental treatment or to a comparison group, which may get a placebo or standard care. The National Institute on Aging notes that placebos are not used when an effective treatment already exists and leaving you without it would put you at risk, and that you are told beforehand if a placebo is part of the design.

Ask whether the trial has an open-label extension: a phase after the main study where everyone who took part can receive the drug. Recent Alzheimer's drug trials, including Clarity AD, have offered one.

What protects me if I join?

An ethics board reviews the study before it starts, you sign a consent form after it is explained to you, an independent board watches the safety data, and you can leave whenever you want.

The NIA describes the main protections. An Institutional Review Board reviews most US studies to make sure the risks do not outweigh the possible benefits. Informed consent means the team explains the purpose, procedures, risks and benefits, and you can keep asking questions throughout. Treatment trials have a Data and Safety Monitoring Board that can stop a study early if a drug is not working or is causing harm.

And you can leave a study at any time, for any reason. The consent form you sign is not a contract.

Who pays for it?

The sponsor usually provides the experimental drug. Medicare covers the routine care around a qualifying trial. Ask about travel costs directly.

Medicare's clinical trial policy covers the routine costs of qualifying clinical trials: the care you would get anyway, the services needed to give the experimental treatment and monitor you, and treatment of complications. It does not pay for the experimental item itself, which the sponsor usually supplies, or for tests done purely for the study's data.

Many studies reimburse travel, parking or time. Ask the study coordinator what is covered before your first visit, not after.

How do I find a trial, and what should I ask?

Start with a matching service and a research center near you, then ask the coordinator a short list of questions before you agree to anything.

Where to look:

• Alzheimer's Association TrialMatch, a free service that matches you to studies based on your diagnosis and location.
• ClinicalTrials.gov, the federal registry of trials, searchable by condition and location.
• An NIA-funded Alzheimer's Disease Research Center, if one is near you. These centers at major medical institutions run studies and often have their own research registries.
• Your neurologist, who may know about studies at your own health system.

Questions to ask before you sign:

• What is the study testing, and what phase is it in?
• Could I get a placebo, and is there an open-label phase afterward?
• How often are the visits, how long do they take, and what happens at each one?
• What are the known risks, and what happens if I have a side effect?
• Will I learn my results, such as my amyloid scan, and will I learn the trial's overall results?
• What does my study partner need to do?
• Is anything paid for, such as travel?

One warning sign: a legitimate trial does not charge you to receive the experimental treatment. Clinics that sell unproven treatments, including some that call themselves research programs, usually do.